Bayer expands Kerendia heart failure program to 15,000 patients as it plans to start three Phase III trials
Bayer is working on expanding the label for its chronic kidney disease drug Kerendia, announcing three new trials to investigate it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
